AIT Bioscience Welcomes New Chief Scientific Officer - AIT BioscienceAIT Bioscience

AIT Bioscience Welcomes New Chief Scientific Officer

AIT Bioscience, LLC has named Shelby R. Anderson, Ph.D., as Chief Scientific Officer (CSO). Anderson replaces Ronald E. Shoup, Ph.D. in this role. Shoup served as the company’s scientific founder and has held executive leadership roles since September 2008, most recently as CSO since 2013. Shoup has been responsible for motivating the AIT Bioscience team to think differently and see where new technologies could improve quality and efficiency. Shoup will remain part of AIT Bioscience in the role of Executive Advisor where he will continue to leverage his more than thirty-five years of entrepreneurship and scientific expertise to provide high quality bioanalytical solutions.

 

AIT Bioscience is an innovative bioanalytical laboratory uniquely positioned to provide solutions in both large molecule and small molecule analytical methods development, validation and analysis using the industry’s only fully integrated electronic laboratory environment. These capabilities and a customer-first mindset allow the company to deliver the highest quality results for its clients.
“I’m delighted that Shelby is joining AIT Bioscience. Shelby is respected in the industry as an innovative scientist,” said Terri Pascarelli, Chief Executive Officer of AIT Bioscience. “Her scientific skills and deep expertise will benefit our clients and enhance our analytical services. Bringing Shelby onto our leadership team further strengthens our company’s exceptional scientific focus. As Executive Advisor, Ron Shoup continues to engage with clients and industry thought-leaders, and Shelby and Ron have a combined leadership depth that bolster our commitment to innovation and outstanding science.”

 

AIT Bioscience clients include US and international pharma, biotech and animal health companies engaged in drug development of novel medical therapies.

 

Ms. Anderson brings more than 20 years of experience in various aspects of ADME and pharmaceutical R&D from early drug discovery through to clinical trial execution and commercialization. Prior to joining AIT Bioscience, she was site head, director of drug metabolism services for Q2 Solutions (previously Quintiles; previously Advion) in Indianapolis, IN. Her background includes roles at Lilly Research Laboratories (Eli Lilly) and Pfizer Research Division in the US and UK. She also spent time as an assistance professor of organic chemistry at Trinity College in Hartford, CT.    

 

Ms. Anderson earned her BA in Chemistry from Carleton College, her Ph.D. in Organic Chemistry from Harvard University and completed her Postdoc work at Yale University.

 

 

Share this with your colleagues.

Categories: News.


Tags: , , ,